ANNX
Annexon Inc
NASDAQ: ANNX · HEALTHCARE · BIOTECHNOLOGY
$5.87
-0.34% today
Updated 2026-04-30
Market cap
$943.59M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.34
Dividend yield
—
52W range
$2 – $7
Volume
2.7M
Annexon Inc (ANNX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — |
| Cost of revenue | $271000.00 | $488000.00 | $493000.00 | $667000.00 | $3.41M | $3.31M | $3.27M | $3.45M | $3.69M |
| Gross profit | $-271000.00 | $-488000.00 | $-493000.00 | $-667000.00 | $-3.41M | $-3.31M | $-3.27M | $-3.45M | $-3.69M |
| Gross margin | — | — | — | — | — | — | — | — | — |
| R&D | $17.85M | $15.53M | $24.52M | $49.27M | $100.07M | $112.50M | $113.76M | $119.45M | $184.70M |
| SG&A | $2.62M | $3.62M | $7.99M | $14.20M | $30.65M | $33.10M | $28.02M | $34.63M | $31.71M |
| Operating income | $-20.48M | $-19.15M | $-32.52M | $-63.47M | $-130.71M | $-145.60M | $-143.72M | $-154.07M | $-216.41M |
| Operating margin | — | — | — | — | — | — | — | — | — |
| EBITDA | $-20.21M | $-18.66M | $-32.02M | $-62.80M | $-128.57M | $-143.49M | $-141.57M | $-134.75M | $-213.76M |
| EBITDA margin | — | — | — | — | — | — | — | — | — |
| EBIT | $-20.48M | $-19.15M | $-32.52M | $-63.47M | $-130.71M | $-145.60M | $-143.72M | $-138.20M | $-216.41M |
| Interest expense | $0.00 | $0.00 | $4.66M | $0.00 | $2.14M | $3.65M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-18.71M | $-18.30M | $-37.18M | $-62.74M | $-127.79M | $-138.29M | $-134.24M | $-138.20M | $-206.69M |
| Net income growth (YoY) | — | +2.2% | -103.1% | -68.7% | -103.7% | -8.2% | +2.9% | -3.0% | -49.6% |
| Profit margin | — | — | — | — | — | — | — | — | — |